{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:35:31Z","timestamp":1794281731385,"version":"4.9.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T00:00:00Z","timestamp":1235347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy for refractory partial seizures in adults with \u22654 partial\u2010onset seizures (simple or complex, with or without secondary generalization) per 4\u2003weeks despite treatment with 1\u20132 antiepileptic drugs (AEDs).<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> This multicenter, parallel\u2010group study had an 8\u2010week, single\u2010blind, placebo baseline phase, after which patients were randomized to placebo (n\u2003=\u2003102) or once\u2010daily ESL 400\u2003mg (n\u2003=\u2003100), 800\u2003mg (n\u2003=\u200398), or 1,200\u2003mg (n\u2003=\u2003102) in the double\u2010blind treatment phase. ESL starting dose was 400\u2003mg; thereafter, ESL was titrated at weekly 400\u2010mg steps to the full maintenance dose (12\u2003weeks).<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> Seizure frequency adjusted per 4\u2003weeks over the maintenance period (primary endpoint) was significantly lower than placebo in the ESL 1,200\u2010mg (p\u2003=\u20030.0003) and 800\u2010mg (p\u2003=\u20030.0028) groups [analysis of covariance (ANCOVA) of log\u2010transformed seizure frequency]. Responder rate was 20% (placebo), 23% (400\u2003mg), 34% (800\u2003mg), and 43% (1,200\u2003mg). Median relative reduction in seizure frequency was 16% (placebo), 26% (400\u2003mg), 36% (800\u2003mg), and 45% (1,200\u2003mg). The most frequent concomitant AEDs were carbamazepine (56\u201362% of patients), lamotrigine (25\u201327%), and valproic acid (22\u201328%). Similar efficacy results were obtained in patients administered ESL with or without carbamazepine as concomitant AED. Discontinuation rates caused by adverse events (AEs) were 3.9% (placebo), 4% (400\u2003mg), 8.2% (800\u2003mg), and 19.6% (1,200\u2003mg). AEs in &gt;10% of any group were dizziness, headache, and diplopia. Most AEs were mild or moderate.<\/jats:p><jats:p><jats:bold><jats:styled-content>Discussion:<\/jats:styled-content>\u2002<\/jats:bold> ESL, 800 and 1,200\u2003mg once\u2010daily, was well tolerated and more effective than placebo in patients who were refractory to treatment with one or two concomitant AEDs.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2008.01946.x","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T09:56:56Z","timestamp":1235383016000},"page":"454-463","source":"Crossref","is-referenced-by-count":229,"title":["Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial\u2010onset seizures: A randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group phase III study"],"prefix":"10.1111","volume":"50","author":[{"given":"Christian","family":"Elger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hal\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Soares\u2010da\u2010Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BIA\u20102093\u2010301 Investigators Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528100-00004"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.10.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0414-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1499-1654.2000.001597.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-17-06826.2003"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"e_1_2_6_9_1","unstructured":"EMEA\/Committee for Proprietary Medicinal Products. (2000)Note for guidance on clinical investigation of medicinal products in the treatment of epileptic disorders.EMEA\/CPMP London 16 November 2000 (CPMP\/EWP\/566\/98 rev 1)."},{"key":"e_1_2_6_10_1","first-page":"1543","volume-title":"Epilepsy: a comprehensive textbook","author":"Fertig EJ","year":"2008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002033420503"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46119"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271104"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.05402.x"},{"key":"e_1_2_6_15_1","volume-title":"Proceedings of the 27th International Epilepsy Congress","author":"Potschka H","year":"2007"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh682"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.10.011"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0391"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410290404"},{"key":"e_1_2_6_20_1","first-page":"1575","volume-title":"Epilepsy: a comprehensive textbook","author":"Tomson T","year":"2008"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01946.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01946.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:58:08Z","timestamp":1697111888000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01946.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01946.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01946.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}